Following a 2023 review of the UK clinical trial landscape, Lord James O鈥橲haughnessy, the former health minister highlighted major change since the report鈥檚 publication, but asked, 鈥淗ow sustainable is this new change in direction?鈥�.
At the Outsourcing in Clinical Trials UK & Ireland conference, O鈥� Shaughnessy and other key opinion leaders said more changes are necessary to improve the UK鈥檚 clinical trial landscape.
The conference, taking place from 11 鈥� 12 June, gathered clinical trial experts from across the world to discuss issues related to the and clinical operations in the UK and Ireland. At a panel discussing recent improvements to the UK clinical trial landscape, prominent figures detailed the key changes that could improve the ecosystem.
Professor Michael Lewis, the scientific director of innovation at the National Institute for Health and Care Research (NIHR), listed achievements since the May review such as changes to the Medicines and Healthcare products Regulatory Agency鈥檚 (MHRA) research framework and new National Health Service (NHS) guidance on . However, all panelists stated that the UK still has space to evolve its clinical trial sector.
鈥淚t feels like we have turned a corner. That is a big achievement, but it is not enough,鈥� says O鈥橲haughnessy. O鈥橲haughnessy published a in May 2023, detailing five main areas for improvement in the country鈥檚 clinical landscape.
Dr. Andrew Ustianowski, the network director at the NIHR鈥檚 North West Regional Research Delivery Network, called attention to issues with the clinical trial timelines. He says that sponsors often bring their clinical trial plans to the UK too late, approaching the US regulatory system first, and then talking to UK regulators months later with plans directed to the US system. O鈥橲haughnessy said that this issue was partially due to a UK tendency to measure the success of the UK regulatory system against its past iterations rather than UK comparators. He offered the potential solution of a streamlined fast-track regulatory process across several global authorities. The former health minister says that several political parties have produced viable approaches to this, including the Labour and Conservative parties. For example, the Labour party鈥檚 鈥淧rescription for growth鈥� outlines such a plan.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataReleased in February, the Labour party鈥檚 report proposed the creation of a Regulatory Innovation Office (RIO) that unifies the Regulation Executive and the secretariat for the Regulatory Horizons Council. The new office would aim to 鈥渕onitor targets for regulatory approval timelines, benchmarked against international comparators鈥�, as per the report, amongst other responsibilities.
